Arbutus Biopharma Stock News

Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) have received a consensus rating of Buy from the six analysts that are covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price target among brokers that have []

Arbutus Biopharma Co. (NASDAQ:ABUS) saw an uptick in trading volume on Wednesday . 814,409 shares were traded during mid-day trading, a decline of 61% from the previous sessions volume of 2,086,054 shares.The stock last traded at $4.40 and had previously closed at $3.20. A number of brokerages recently commented on ABUS. JMP Securities lifted their []

Arbutus Biopharma Co. (NASDAQ:ABUS) shares saw strong trading volume on Wednesday . 814,409 shares changed hands during trading, a decline of 61% from the previous sessions volume of 2,086,054 shares.The stock last traded at $4.40 and had previously closed at $3.20. A number of equities analysts have weighed in on the stock. HC Wainwright reduced []

The patents subject to the court's ruling cover a lipid formulation for nucleic acid delivery, which is essential for Moderna's COVID-19 vaccines.

The stock price of Arbutus Biopharma Corp (NASDAQ: ABUS) increased by over 50% during intraday trading today. This is why it happened.

Arbutus Biopharma Corporation (NASDAQ: ABUS) has announced preliminary data from its Phase 1a/1b trial of AB-836, an oral hepatitis B virus (HBV) capsid inhibitor that interacts with HBV core prote

Arbutus Biopharma Corp (NASDAQ: ABUS) is soaring Wednesday after The Patent Trial and Appeals Board turned down Moderna Inc's (NASDAQ: MRNA) appeal to invalidate two of Arbutus' patents on drug-del

Shares of small-cap biotech Arbutus Biopharma Corporation (NASDAQ: ABUS) are advancing strongly on above-average volume on Wednesday. What Happened: The Patent Trial and Appeals Board has turned down

Nuveen Asset Management LLC bought a new stake in shares of Arbutus Biopharma Co. (NASDAQ:ABUS) in the 2nd quarter, Holdings Channel reports. The fund bought 226,012 shares of the biopharmaceutical companys stock, valued at approximately $685,000. Several other institutional investors have also made changes to their positions in ABUS. Northern Trust Corp grew its stake []

Northern Trust Corp raised its position in Arbutus Biopharma Co. (NASDAQ:ABUS) by 441.9% in the second quarter, HoldingsChannel reports. The fund owned 719,159 shares of the biopharmaceutical companys stock after purchasing an additional 586,456 shares during the quarter. Northern Trust Corps holdings in Arbutus Biopharma were worth $2,179,000 as of its most recent SEC filing. []

During the last session, Arbutus Biopharma Corporation (NASDAQ:ABUS)s traded shares were 0.72 million, with the beta value of the company hitting 2.58. At the end of the trading day, the stocks price was $3.19, reflecting an intraday gain of 2.24% or $0.07. The 52-week high for the ABUS share is $5.87, that puts it down Arbutus Biopharma Corporation (NASDAQ: ABUS) Stock Dropped -21.62% Over A Month Are There Any Chances Of Growth? Read More »

Brokerages expect Arbutus Biopharma Co. (NASDAQ:ABUS) to post ($0.18) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Arbutus Biopharmas earnings, with the highest EPS estimate coming in at ($0.16) and the lowest estimate coming in at ($0.19). Arbutus Biopharma reported earnings per share of []

Equities analysts expect Arbutus Biopharma Co. (NASDAQ:ABUS) to post sales of $3.39 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Arbutus Biopharmas earnings. The highest sales estimate is $3.47 million and the lowest is $3.30 million. Arbutus Biopharma reported sales of $2.39 million during the same []